4512.T
The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of prescription drugs and related healthcare products.
Business. The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of prescription drugs and related healthcare products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of prescription drugs and related healthcare products.
The company maintains a strong liquidity position, with a current ratio of 4.38, indicating that it has more than four times as many current assets as current liabilities. Its cash and equivalents amount to ¥2.95 billion, which provides a buffer against short-term obligations. The company's debt-to-equity ratio is 0.01, suggesting a conservative capital structure with minimal reliance on debt financing.
Profitability metrics reveal a mixed performance. The company's return on equity (ROE) is 0.56%, and its return on assets (ROA) is 0.43%, both of which are below the industry median for pharmaceutical companies. This suggests that the company is not generating returns at a rate that is typical for its industry. Additionally, the company reported an operating loss of ¥461 million, which is a significant deviation from profitability.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification may expose the company to higher risk if market conditions in its primary operating region change.
Looking ahead, the company's revenue is expected to remain flat or decline slightly in the next fiscal year, based on the current outlook and historical performance. The operating loss in the most recent fiscal year suggests that the company may face challenges in maintaining or improving its profitability in the near term.
The company's risk profile is characterized by low liquidity and dilution risk, with no immediate filing-based flags detected. However, the operating loss and low ROE indicate potential operational inefficiencies or market pressures that could affect future performance. The company has not issued any new shares recently, and there is no indication of dilution pressure in the near term.
Recent filings and transcripts do not highlight any major events or strategic shifts that would significantly impact the company's operations or financial position. The company's financial statements and disclosures remain consistent with its historical reporting, with no material changes in accounting policies or business strategy noted.
- The company has a strong liquidity position with a current ratio of 4.38 and ¥2.95 billion in cash and equivalents.
- The company's profitability is weak, with an operating loss of ¥461 million and ROE of 0.56%.
- The company's revenue is concentrated in a single business segment, with no significant geographic diversification.
- The company's capital structure is conservative, with a debt-to-equity ratio of 0.01.
- The company faces potential challenges in maintaining profitability, as indicated by its recent operating loss and low ROE.
- There are no immediate liquidity or dilution risks, but the company's financial performance may require closer monitoring in the near term.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 4512.T Market data — financials · 2026-05-26